Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Navicare Biotech CoROCO:8472 -3.07%53 EBITDA Margin % is 8.71% as of Dec. 2025, which is 50% above its 10-year median of 5.79. GuruFocus rates ROCO:8472 with a GF Score™ of 53/100 and a GF Value™ of NT$44.21 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,125 Retail - Cyclical companies, Navicare Biotech Co ranks worse than 80.71% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Navicare Biotech Co's EBITDA for the
three
months ended in Dec. 2025 was NT$10.7 Mil. Navicare Biotech Co's Revenue for the
three
months ended in Dec. 2025 was NT$123.4 Mil. Therefore, Navicare Biotech Co's EBITDA margin for the quarter that ended in Dec. 2025 was 8.71%.
Navicare Biotech Co (ROCO:8472) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Navicare Biotech Co EBITDA Margin % Related Terms
Navicare Biotech Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Navicare Biotech Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:8472 vs AMZN, BABA, PDD: EBITDA Margin % Comparison
For the Internet Retail subindustry, Navicare Biotech Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Navicare Biotech Co EBITDA Margin % vs Retail - Cyclical Industry
For the Retail - Cyclical industry and Consumer Cyclical sector, Navicare Biotech Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Navicare Biotech Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Navicare Biotech Co (ROCO:8472) has a EBITDA Margin % of 8.71% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Navicare Biotech Co and its competitors. This is 50% above median its historical median of 5.79. According to the industry distribution chart, Navicare Biotech Co ranks #908 out of 1125 companies in the Retail - Cyclical industry, placing it in the top 80.7%.
Is Navicare Biotech Co's EBITDA Margin % too high?
Navicare Biotech Co's current EBITDA Margin % of 8.71% is 50% above median its 10-year median of 5.79. The Retail - Cyclical industry median EBITDA Margin % is 7.45. Navicare Biotech Co's value of 8.71% is 16.9% above this industry median. Based on the distribution chart, Navicare Biotech Co ranks #908 out of 1125 companies in the Retail - Cyclical industry, which is in the bottom quartile relative to peers. Overall, Navicare Biotech Co has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Navicare Biotech Co's EBITDA Margin % compare to AMZN and BABA?
According to the Retail - Cyclical industry distribution chart, Navicare Biotech Co ranks #908 out of 1125 companies for EBITDA Margin %. This places Navicare Biotech Co in the lower half of its industry. The industry median EBITDA Margin % is 7.45. Navicare Biotech Co's value of 8.71% is 16.9% above this benchmark. While the company's 10-year median is 5.79 vs. the industry median of 7.45, Navicare Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Retail - Cyclical company?
The median EBITDA Margin % among Retail - Cyclical companies is 7.45, based on 1,125 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Navicare Biotech Co's current EBITDA Margin % of 8.71% is 16.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Navicare Biotech Co and its competitors. For the Retail - Cyclical industry, the median EBITDA Margin % is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Navicare Biotech Co's current EBITDA Margin % is 8.71%, which is 50% above median its own 10-year median of 5.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Navicare Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Navicare Biotech Co (ROCO:8472) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$44.21, compared to a current price of NT$79.00 — trading 78.7% above its estimated fair value. The current EBITDA Margin % is 8.71%, which is 50% above median its 10-year median of 5.79 and 16.9% above the Retail - Cyclical industry median of 7.45. Navicare Biotech Co's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Navicare Biotech Co (ROCO:8472), the current EBITDA Margin % is 8.71% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Navicare Biotech Co (ROCO:8472) Overvalued in 2026?
Based on GuruFocus' analysis, Navicare Biotech Co stock appears to be overvalued.
The current stock price of NT$79.00 is trading 78.7% above its estimated GF Value™ of NT$44.21.
GuruFocus considers Navicare Biotech Co to be Significantly Overvalued.
Key valuation signals for ROCO:8472:
EBITDA Margin %: 8.71% (50% above median its 10-year median of 5.79)
GF Value™: NT$44.21 vs. price of NT$79.00 (78.7% above fair value)
Industry Position: 16.9% above the Retail - Cyclical median (#908 of 1125)
No single metric tells the full story. See the ROCO:8472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8472 has been successfully added to your 
